Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib plus hydroxychloroquine versus hydroxychloroquine alone for active primary Sjögren's syndrome
ChiCTR2300069222Phase 4Completed
- Sponsor
- Beijing Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib and hydroxychloroquine in primary Sjögren's syndrome (2 arms), sponsored by Beijing Hospital. Primary endpoint: Change from baseline in ESSDAI score at Week 12. Started Mar 2023; status: completed.
02
Drugs
tofacitinibhydroxychloroquine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2300069222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069222.